MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2026-27)
- Udyam number
- UDYAM-GJ-01-0039004
Market Cap
₹44.54 Cr
JFLLIFE-SM · NSE
Share Price
₹13.50
0.00% today
Revenue
₹131 Cr
FY 2025-26 · +60.1% YoY
EBITDA
₹11.71 Cr
Margin 8.9%
Net Profit
₹6.39 Cr
FY 2025-26 · +54.0% YoY
P/E (TTM)
4.7x
P/B 0.8x
ROE
15.0%
ROCE 18.2%
Debt / Equity
0.38
Interest cover 19.9x
About JFL Life Sciences Limited
Data last updated:
JFL Life Sciences Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 25 April 2010 and has been in existence for over 16 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ2010PLC060417. Its GSTIN is 24AACCJ5298E1ZJ (Gujarat). It is a listed company as per MCA records. Its shares are listed on NSE: JFLLIFE.
The company has an authorised share capital of ₹67.5 Cr and a paid-up capital of ₹33 Cr. It was formerly known as Jfl Life Sciences Private Limited. It is led by directors including Smiral Ashwinkumar Patel (Managing Director) and Tejal Smiral Patel (Whole-Time Director).
Its last annual general meeting (AGM) was held on 25 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Ahmedabad, Gujarat.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹131.38 Cr, a growth of 60.1% compared to the previous year. For the same year it recorded a net profit of ₹6.39 Cr (net margin 4.9%) and EBITDA of ₹11.71 Cr (EBITDA margin 8.9%). The net worth stands at ₹45.87 Cr (up 16.2% YoY). Total assets are valued at ₹67.74 Cr (up 35% YoY).
The company is associated with 1 brand: Jfl Life Sciences. As per MCA filings, the company has open charges of ₹24.22 Cr and satisfied charges of ₹16.19 Cr on record. Court records list 7 cases involving the company, including 7 filed against it. The company has 14 deals on record (5 funding rounds, 5 secondary share transfers, 3 rights issues), with disclosed funding of ₹4.45 Cr; the latest was in September 2022.
JFL Life Sciences Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-01-0039004). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website jfllifesciences.com.
Company details
CIN L24230GJ2010PLC060417
Registration Number 060417
Incorporation Date 25 April 2010
ROC Ahmedabad
Listing Status Listed (NSE: JFLLIFE)
Company Status Active
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-GJ-01-0039004
CIN history
JFL Life Sciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230GJ2010PLC060417, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230GJ2010PLC060417 | Current |
| U24230GJ2010PLC060417 | Previous |
| U24230GJ2010PTC060417 | Previous |
Key People
Smiral Ashwinkumar Patel Managing Director Tejal Smiral Patel Whole-Time Director Bhavna Basantbhai Shah Director Recognitions & Rankings of JFL Life Sciences
Contact details
JFL Life Sciences Limited's registered office is in Ahmedabad, Gujarat. Its website is jfllifesciences.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address309 Satyam Mall Opp. Saman Complex Nr. Vishweshwar Mahadev Mandir Settelit, E, Ahmedabad, Gujarat, India – 380015
- IndustryPharma, Drug Formulation & Development
To see the full contact details of JFL Life Sciences Limited, buy the company report.
Comprehensive company report
JFL Life Sciences Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
JFL Life Sciences operates one associated brand: JFL LIFE SCIENCES. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| General tablets, capsules, and dry powder injections are manufactured. | jfllifesciences.com |
Business activity
The main business activity of JFL Life Sciences is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations |
To see the full business activity and turnover split of JFL Life Sciences Limited, buy the company report.
Financials of JFL Life Sciences Limited
FY 2025-26 filings availableJFL Life Sciences Limited reported revenue of ₹131.38 Cr (up 60.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹131 Cr
+60.1% YoY
EBITDA
₹11.71 Cr
+43.0% YoY
Profit After Tax
₹6.39 Cr
+54.0% YoY
Net Worth
₹45.87 Cr
+16.2% YoY
Total Assets
₹67.74 Cr
+35.0% YoY
Total Debt
₹21.73 Cr
+105.2% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 131 | 82.04 | 46.55 | 42.83 | 33.59 | 32.77 | 30.17 |
| Revenue growth | +60.1% | +76.2% | +8.7% | +27.5% | +2.5% | +8.6% | - |
| EBITDA | 11.71 | 8.19 | 4.55 | 3.93 | 5.36 | 2.16 | 1.87 |
| EBITDA margin | +8.9% | +10.0% | +9.8% | +9.2% | +16.0% | +6.6% | +6.2% |
| Profit before tax | 8.59 | 6.13 | 3.80 | 3.72 | 3.80 | 0.74 | 0.50 |
| Net profit | 6.39 | 4.15 | 3.30 | 2.81 | 2.81 | 0.54 | 0.36 |
| Net profit margin | +4.9% | +5.1% | +7.1% | +6.6% | +8.4% | +1.7% | +1.2% |
| EPS (₹) | 1.94 | 1.26 | 3.01 | 2.55 | 3.50 | 10.91 | 8.52 |
| Balance sheet | |||||||
| Total assets | 67.74 | 50.18 | 41.37 | 39.54 | 27.14 | 23.75 | 14.75 |
| Net worth | 45.87 | 39.46 | 35.58 | 32.27 | 11.29 | 6.88 | 5.37 |
| Total debt | 21.73 | 10.59 | 5.69 | 7.18 | 15.85 | 16.82 | 9.33 |
| Cash & bank | 1.46 | 0.06 | 0.03 | 0.06 | 0.19 | 0.04 | 0.30 |
| Net working capital | 53.35 | 38.08 | 27.86 | 31.81 | 18.36 | 15.35 | 8.89 |
| Cash flow | |||||||
| Cash from operations | (4.33) | (3.56) | 8.36 | (9.07) | 2.32 | (5.87) | 3.21 |
| Cash from investing | (3.94) | 0.02 | (6.07) | 0.87 | (0.71) | (1.64) | (2.76) |
| Cash from financing | 9.10 | 3.54 | (2.31) | 8.07 | (1.46) | 7.25 | (0.19) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 98.65 | 11.10 | 63.05 | 26.84 | 29.91 | 11.59 | 11.73 | 21.25 |
| Revenue growth (YoY) | +229.8% | -4.2% | +437.5% | +26.3% | -24.3% | +21.5% | - | - |
| Other income | 0.00 | 0.02 | 0.04 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Total expenses | 92.00 | 9.01 | 59.54 | 23.49 | 26.99 | 9.65 | 10.36 | 19.90 |
| EBITDA | 6.65 | 2.09 | 3.51 | 3.35 | 2.92 | 1.94 | 1.37 | 1.35 |
| EBITDA margin | +6.7% | +18.8% | +5.6% | +12.5% | +9.8% | +16.7% | +11.7% | +6.4% |
| Depreciation | 0.32 | 0.32 | 0.27 | 0.27 | 0.27 | 0.26 | 0.36 | 0.16 |
| Interest | 0.68 | 0.30 | 1.03 | 0.38 | 0.44 | 0.24 | 0.33 | 0.20 |
| Profit before tax | 5.65 | 1.49 | 2.25 | 2.71 | 2.22 | 1.44 | 0.68 | 0.99 |
| Tax | 1.42 | 0.38 | 0.59 | 0.68 | 0.24 | 0.69 | 0.60 | 0.25 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 12 Nov 2026
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 98.65 | 11.10 | 63.05 | 26.84 | 29.91 | 11.59 | 11.73 | 21.25 |
| Revenue growth (YoY) | +229.8% | -4.2% | +437.5% | +26.3% | -24.3% | +21.5% | - | - |
| Other income | 0.00 | 0.02 | 0.04 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Total expenses | 92.00 | 9.01 | 59.54 | 23.49 | 26.99 | 9.65 | 10.36 | 19.90 |
| EBITDA | 6.65 | 2.09 | 3.51 | 3.35 | 2.92 | 1.94 | 1.37 | 1.35 |
| EBITDA margin | +6.7% | +18.8% | +5.6% | +12.5% | +9.8% | +16.7% | +11.7% | +6.4% |
| Depreciation | 0.32 | 0.32 | 0.27 | 0.27 | 0.27 | 0.26 | 0.36 | 0.16 |
| Interest | 0.68 | 0.30 | 1.03 | 0.38 | 0.44 | 0.24 | 0.33 | 0.20 |
| Profit before tax | 5.65 | 1.49 | 2.25 | 2.71 | 2.22 | 1.44 | 0.68 | 0.99 |
| Tax | 1.42 | 0.38 | 0.59 | 0.68 | 0.24 | 0.69 | 0.60 | 0.25 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 131 | 82.04 | 46.55 | 42.83 | 33.59 | 32.77 | 30.17 |
| Revenue growth | +60.1% | +76.2% | +8.7% | +27.5% | +2.5% | +8.6% | - |
| Other income | 0.07 | 0.01 | 0.52 | 1.64 | 0.89 | 0.09 | 0.03 |
| Total expenses | 120 | 73.85 | 42.00 | 38.90 | 28.23 | 30.61 | 28.30 |
| Employee cost | 0.00 | 1.01 | 2.01 | 1.83 | 1.43 | 0.98 | 1.25 |
| EBITDA | 11.71 | 8.19 | 4.55 | 3.93 | 5.36 | 2.16 | 1.87 |
| EBITDA margin | +8.9% | +10.0% | +9.8% | +9.2% | +16.0% | +6.6% | +6.2% |
| Depreciation | 1.08 | 0.99 | 0.44 | 0.43 | 0.37 | 0.28 | 0.24 |
| Interest | 2.11 | 1.08 | 0.83 | 1.42 | 2.08 | 1.23 | 1.16 |
| Profit before tax | 8.59 | 6.13 | 3.80 | 3.72 | 3.80 | 0.74 | 0.50 |
| Tax | 2.20 | 1.98 | 0.50 | 0.91 | 0.99 | 0.20 | 0.14 |
| Net profit | 6.39 | 4.15 | 3.30 | 2.81 | 2.81 | 0.54 | 0.36 |
| Net profit margin | +4.9% | +5.1% | +7.1% | +6.6% | +8.4% | +1.7% | +1.2% |
| EPS (₹) | 1.94 | 1.26 | 3.01 | 2.55 | 3.50 | 10.91 | 8.52 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 33.00 | 33.00 | 11.00 | 11.00 | 8.02 | 0.50 | 0.42 |
| Reserves & surplus | 12.87 | 6.46 | 24.58 | 21.27 | 3.27 | 6.38 | 4.95 |
| Shareholders' funds (net worth) | 45.87 | 39.46 | 35.58 | 32.27 | 11.29 | 6.88 | 5.37 |
| Secured loans | 21.18 | 10.19 | 5.69 | 7.18 | 13.53 | 12.91 | 5.87 |
| Unsecured loans | 0.55 | 0.40 | 0.00 | 0.00 | 2.32 | 3.91 | 3.46 |
| Total debt | 21.73 | 10.59 | 5.69 | 7.18 | 15.85 | 16.82 | 9.33 |
| Total liabilities | 67.74 | 50.18 | 41.37 | 39.54 | 27.14 | 23.75 | 14.75 |
| Assets | |||||||
| Gross block | 17.21 | 13.83 | 13.08 | 8.92 | 8.81 | 7.79 | 6.06 |
| Net block | 14.54 | 12.24 | 12.48 | 6.80 | 7.13 | 6.51 | 5.05 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 34.55 | 23.24 | 15.83 | 12.72 | 14.96 | 5.74 | 3.75 |
| Sundry debtors | 53.26 | 34.95 | 25.15 | 22.48 | 19.80 | 11.81 | 12.66 |
| Cash & bank balances | 1.46 | 0.06 | 0.03 | 0.06 | 0.19 | 0.04 | 0.30 |
| Loans & advances | 2.23 | 1.25 | 2.12 | 5.88 | 4.35 | 2.88 | 1.67 |
| Total current assets | 91.50 | 59.50 | 43.13 | 41.14 | 39.30 | 20.47 | 18.38 |
| Total current liabilities | 38.15 | 21.42 | 15.27 | 9.33 | 20.94 | 5.12 | 9.49 |
| Net working capital | 53.35 | 38.08 | 27.86 | 31.81 | 18.36 | 15.35 | 8.89 |
| Total assets | 67.74 | 50.18 | 41.37 | 39.54 | 27.14 | 23.75 | 14.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.03 | 0.03 | 0.06 | 0.19 | 0.04 | 0.30 | 0.03 |
| Net cash from operating activities | (4.33) | (3.56) | 8.36 | (9.07) | 2.32 | (5.87) | 3.21 |
| Net cash from investing activities | (3.94) | 0.02 | (6.07) | 0.87 | (0.71) | (1.64) | (2.76) |
| Net cash from financing activities | 9.10 | 3.54 | (2.31) | 8.07 | (1.46) | 7.25 | (0.19) |
| Net change in cash | 0.83 | 0.00 | (0.03) | (0.13) | 0.15 | (0.26) | 0.27 |
| Closing cash | 1.46 | 0.06 | 0.03 | 0.06 | 0.19 | 0.04 | 0.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +60.1% | +76.2% | +8.7% | +27.5% | +2.5% | +8.6% | - |
| EBITDA growth | +43.0% | +80.0% | +15.8% | -26.7% | +148.2% | +15.5% | - |
| PBT growth | +39.9% | +61.6% | +2.2% | -2.1% | +413.5% | +48.0% | +19.1% |
| Net income growth | +54.0% | +25.8% | +17.4% | 0.0% | +420.4% | +50.0% | - |
| Revenue CAGR (3Y) | +45.3% | +34.7% | +12.4% | +12.4% | +1.9% | - | - |
| EBITDA CAGR (3Y) | +43.9% | +15.2% | +28.2% | +28.1% | +59.5% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +4.9% | +5.1% | +7.1% | +6.6% | +8.4% | +1.7% | +1.2% |
| Return on capital employed | +18.2% | +15.8% | +11.4% | +15.4% | +23.1% | +10.2% | +11.8% |
| Return on net worth | +15.0% | +11.1% | +9.8% | +12.9% | +30.9% | +8.8% | +6.9% |
| Debt / equity | 0.38 | 0.22 | 0.19 | 0.53 | 1.80 | 2.13 | 1.71 |
| Long-term debt / equity | 0.09 | 0.02 | 0.03 | 0.22 | 0.91 | 0.78 | 0.41 |
| Interest cover | 19.85 | 14.98 | 20.19 | 40.57 | 41.68 | 65.43 | 71.17 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 8.47 | 6.10 | 4.23 | 4.83 | 4.05 | 4.73 | 6.48 |
| Inventory turnover | 4.55 | 4.20 | 3.26 | 3.09 | 3.25 | 6.91 | 11.05 |
| Debtors turnover | 2.98 | 2.73 | 1.95 | 2.03 | 2.13 | 2.68 | 2.70 |
| EPS (₹) | 1.94 | 1.26 | 3.01 | 2.55 | 3.50 | 10.91 | 8.52 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 13.90 | 11.96 | 32.35 | 29.34 | 14.08 | 138.28 | 127.11 |
To see the full year-wise statements and ratios of JFL Life Sciences Limited, buy the company report.
Board of directors of JFL Life Sciences Limited
JFL Life Sciences has 6 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bhavna Basantbhai Shah | Director | 10 Feb 2022 | 4 Years 9 Months | Current |
| Manishkumar Jasvantlal Patel | Director | 10 Feb 2022 | 4 Years 9 Months | Current |
| Sonu Lalitkumar Jain Also directs: Achyut Healthcare Limited | Director | 18 Jan 2022 | 4 Years 9 Months | Current |
| Smiral Ashwinkumar Patel Also directs: JFL Healthcare Private Limited | Managing Director | 18 Jan 2022 | 4 Years 9 Months | Current |
| Tejal Smiral Patel Also directs: JFL Healthcare Private Limited | Whole-Time Director | 18 Jan 2022 | 4 Years 9 Months | Current |
| Khyati Bhavya Shah Also directs: Qualitas Consultech LLP, Qualitas Accountants LLP, Sakar Healthcare Limited and 5 more | Director | 11 Aug 2025 | 1 Years 3 Months | Current |
Auditor
JFL Life Sciences Limited is audited by Doshi Doshi & Co. for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Doshi Doshi & Co. | FY 2025 | 153683W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 67.50%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 32.50%.
Sep 2026
QUARTER
67.50% Promoters
32.50% Retail & Others
Promoter holding - history
Now 67.50% · Sep 2026High 67.50% · Dec 2025Low 67.50% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 67.50% | 67.50% | 67.50% | 67.50% |
| Public | 32.50% | 32.50% | 32.50% | 32.50% |
Charges & borrowings
Open charges
₹24.22 Cr
Satisfied charges
₹16.19 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 05 Jan 2026 | 101224227 | Others | ₹92.8 Lakh | Open | |
| 07 Nov 2025 | 101215342 | Others | ₹6.5 Cr | Open | |
| 08 Apr 2024 | 100908472 | Others | ₹16.79 Cr | Open | |
| 28 Dec 2020 | 100410498 | Others | ₹3.74 Cr | Satisfied | |
| 08 Oct 2020 | 100379006 | Sidbi | ₹3 Cr | Satisfied |
To see the full charge records of JFL Life Sciences Limited, buy the company report.
Total charge records: 8 View all charges
Deals & funding
JFL Life Sciences Limited has 14 deals on record (5 funding rounds, 5 secondary share transfers, 3 rights issues), with disclosed funding of ₹4.45 Cr; the latest was in September 2022.
Total deals
14
Funding rounds
5
Secondary share transfers
5
Rights issues
3
IPO
1
Disclosed funding
₹4.45 Cr
Deals on record (5 of 14)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2022 | IPO | ₹18.17 Cr | Investors: IPO Shareholders - JFL Life Sciences Limited, Econo Broking Private Limited , 2 individuals |
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: Zenith Medicine Private Limited , 3 individuals Seller: 2 individuals |
| Jan 2022 | Funding round | ₹1.56 Cr | Investors: 2 individuals |
| Jan 2021 | Secondary share transfer | Undisclosed | Buyer: Smiral Ashwinkumar Patel HUF, an individual Seller: Valaenza Pharmace Uticals Private Limited, 3 individuals |
| Jul 2020 | Rights issue | ₹95.5 Lakh | Investors: 2 individuals |
To see the full deal history of JFL Life Sciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
JFL Life Sciences Limited has 7 court cases on record: 7 filed against it. All cases are disposed.
Total cases
7
Filed against the company
7
Disposed
7
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 7 | 7 | 0 |
Cases on record (4 of 7)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, New Delhi, Delhi | Cheque dishonour complaint | Filed against the company by Moneywise Financial Services Pvt Ltd | Disposed |
| District court, Thane, Maharashtra | Court case (Sum.Civ.Suit) | Filed against the company by Jal Extrusion Private Ltd. Through Mr. Aliasgar Shabbir Rassiwala | Disposed |
| District court, Mumbai City Civil Court, Maharashtra | Commercial matter | Filed against the company by M/S Haresh Chemicals | Disposed |
| District court, Mumbai City Civil Court, Maharashtra | Court case (Summons For Judgement) | Filed against the company by M/S Haresh Chemicals | Disposed |
To see the full case history of JFL Life Sciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for JFL Life Sciences Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
JFL Life Sciences has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AACCJ5298E1ZJ | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of JFL Life Sciences Limited, buy the company report.
Recent activity
JFL Life Sciences Limited has 10 board changes on record since 2022: 8 appointments and 2 cessations. The latest: Khyati Bhavya Shah was appointed as Director on 11 Aug 2025.
AGM
Jfl Life Sciences Limited last Annual general meeting of members was held on 25 Aug 2026 as per latest MCA records.
Charges
A charge with Others of Rs. 16.79 Cr registered on 08 Apr 2024 with Charge ID 100908472 was modified on 29 May 2026.
Filing
Jfl Life Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with Others amounted to Rs. 0.93 Cr with Charge ID 101224227 was registered on 05 Jan 2026.
Charges
A charge with Others amounted to Rs. 6.50 Cr with Charge ID 101215342 was registered on 07 Nov 2025.
Appointed
Khyati Bhavya Shah was appointed as Director.
Ceased
Amita Chhaganbhai Pragada ceased to be Additional Director.
Appointed
Amita Chhaganbhai Pragada was appointed as Additional Director.
Charges
A charge registered on 27 Apr 2012 via Charge ID 10356609 with State Bank Of India was fully satisfied on 18 Apr 2024.
Charges
A charge with Others amounted to Rs. 16.79 Cr with Charge ID 100908472 was registered on 08 Apr 2024.
Ceased
Bhaumik Sanjaykumar Shah ceased to be CFO.
Charges
A charge with State Bank Of India of Rs. 8.71 Cr registered on 27 Apr 2012 with Charge ID 10356609 was modified on 29 Nov 2022.
16 earlier events are in the company report.
News
Frequently asked questions
JFL Life Sciences is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 25 April 2010 (16+ years old) and is registered under CIN L24230GJ2010PLC060417. Listed on NSE: JFLLIFE.
JFL Life Sciences reported revenue of ₹131.38 Cr for FY 2025-26 (up 60.1% YoY) based on standalone financials.
JFL Life Sciences has 6 current directors:
- Smiral Ashwinkumar Patel - Managing Director
- Tejal Smiral Patel - Whole-Time Director
- Bhavna Basantbhai Shah - Director
- Manishkumar Jasvantlal Patel - Director
- Sonu Lalitkumar Jain - Director
- Khyati Bhavya Shah - Director
The latest financial statements of JFL Life Sciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 August 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of JFL Life Sciences is 24AACCJ5298E1ZJ, registered in Gujarat.
The CIN (Corporate Identification Number) of JFL Life Sciences is L24230GJ2010PLC060417. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. JFL Life Sciences is a listed company as per MCA records. Its shares are listed on NSE (symbol: JFLLIFE).
JFL Life Sciences has 7 court cases on record: 7 filed against it.
JFL Life Sciences was incorporated on 25 April 2010, making it 16+ years old. It is registered with the Registrar of Companies, Ahmedabad.
JFL Life Sciences has 14 deals on record (5 funding rounds, 5 secondary share transfers, 3 rights issues), with disclosed funding of ₹4.45 Cr; the latest was in September 2022.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages